Yahoo Finance McKesson (MCK) to Report Q4 Earnings: Is a Beat in Store?
McKesson Corporation MCK is scheduled to report fiscal fourth-quarter 2023 results on May 8, after market close.
The company delivered an earnings surprise of 8.8% in the last reported quarter. Its earnings beat estimates in two of the trailing four quarters and missed the same twice, the average surprise being 3.42%.
Q4 Estimates
The Zacks Consensus Estimate for McKesson’s earnings is pegged at $7.16 per share, implying an improvement of 22.8% from the prior-year quarter’s figure. The same for revenues stands at $68.18 billion, indicating a surge of 3.1% from the year-ago reported number.
Factors to Note
McKesson’s fiscal fourth-quarter results are expected to reflect segmental strength.
The U.S. Pharmaceutical and Specialty Solutions segment is likely to have acted as a key growth driver in the soon-to-be-reported quarter. The consensus mark for this segment’s revenues stands at $60.6 billion, indicating an improvement of 13% from the prior-year quarter’s level.
The segment is expected to have benefited from market growth and higher volumes from retail national account customers. However, branded-to-generic conversions might have weighed on its performance. MCK’s broad spectrum of specialty biopharmaceutical providers and manufacturers is likely to have contributed to its performance.
Growth and improvement in the primary care business, and contribution from kitting, storage and distribution of ancillary supplies to the U.S. government's COVID-19 vaccine program are likely to have positively impacted the Medical-Surgical Solutions segment.
McKesson’s collaboration with the U.S. government over COVID-19 vaccine distribution highlighted its role in the COVID-19 response. However, COVID-19 tests, and kitting storage and distribution of ancillary supplies might have declined during the quarter.
Continued growth in the Medical-Surgical and Prescription Technology Solutions segments is expected to have benefited the company’s top line in the to-be-reported quarter. Growth in the primary care business and higher technology services revenues are likely to have driven segmental performance.
McKesson Corporation Price and Consensus
McKesson Corporation price-consensus-chart | McKesson Corporation Quote
The top-line estimates for Medical-Surgical segment and Prescription Technology Solutions segment are pegged at $2.8 billion and $1.1 billion, respectively.
Meanwhile, divesture of businesses outside the United States, especially in Europe, might have led to loss of sales during quarter, resulting in lower revenue growth. Interest expenses are likely to have increased amid rising interest-rate regime, hurting the bottom line.
Expected Earnings Beat
Our proven model predicts an earnings beat for McKesson this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate ($7.22 per share) and the Zacks Consensus Estimate, is +0.84% for McKesson.
Zacks Rank: McKesson currently carries a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Other Stocks Worth a Look
Here are a few other medical stocks worth considering, as these too have the right combination of elements to beat on earnings this reporting cycle:
PerkinElmer PKI has an Earnings ESP of +1.66% and a Zacks Rank of 3 at present. PKI has an estimated long-term growth rate of 46.5%.
PerkinElmer’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.65%.
Aptinyx Inc. APTX has an Earnings ESP of +19.23% and a Zacks Rank of 2 at present. APTX has an estimated growth rate of 42.6% for 2024.
Aptinyx’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6.6%.
BellRing Brands, Inc. BRBR has an Earnings ESP of +1.38% and a Zacks Rank of 2 at present. BRBR has an estimated long-term growth rate of 12.7%.
BellRing Brands’ earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.1%.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
McKesson Corporation (MCK) : Free Stock Analysis Report
Revvity Inc. (PKI) : Free Stock Analysis Report
Aptinyx Inc. (APTX) : Free Stock Analysis Report
BellRing Brands Inc. (BRBR) : Free Stock Analysis Report
